Bayer had a better ending than expected at the beginning of 2021. Crop Science especially was better off, benefiting from the greater glyphosate shortage and the strong position in corn and soybeans. Pharma was once again driven by its drag horses, but management warned of some tougher times in 2022. Consumer Health continued to perform well.
Bayer reported a strong beat to the consensus FY net income line (+75.4%); we had been too cautious at many levels.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Flexing muscles in 2021
Bayer had a better ending than expected at the beginning of 2021. Crop Science especially was better off, benefiting from the greater glyphosate shortage and the strong position in corn and soybeans. Pharma was once again driven by its drag horses, but management warned of some tougher times in 2022. Consumer Health continued to perform well.
Bayer reported a strong beat to the consensus FY net income line (+75.4%); we had been too cautious at many levels.